Intelligence · Clinical Development
Pipeline search results
Programs matching “treatment” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 270 pipeline programs matching "treatment" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
160902
Takeda
Primary Immunodeficiency Diseases (PID)
1 trial -
2.16/VI/22
Cardiol Therapeutics
Patients with functionally single ventricle (FSV - functionally single ventricle) after Fontan operation. The term "functionally single ventricle" refers to congenital heart defects in which one of the ventricles is not fully developed and/or one of the valves is atresia/hypoplastic as a result, it is not possible to correct the intracardiac defect. Then, there are indications for the Fontan operation, i.e. a palliative procedure - total cavo-pulmonary connection (TCPC). In patients with a functionally single ventricle, more than one operation is necessary to separate the systemic and pulmonary circulation. As a result of these procedures, Fontan circulation is created, which consists in bypassing the right heart chambers and directing the venous blood to the pulmonary artery. This leads to the removal of the right-to-left shunt and improvement of arterial blood saturation and reduction of volume overload of the systemic ventricle. At the same time, there is an increase in systemic venous pressure and a decrease in cardiac output. Low pulmonary resistance in these patients is crucial for maintaining optimal hemodynamic conditions both at rest and especially during exercise. Even a slight increase in pulmonary resistance leads to reduced pulmonary blood flow, reduced initial depression of a single ventricle, and consequently to reduced cardiac output and worsened exercise tolerance. Thus, pulmonary resistance in these patients should be not only normal, but also as low as possible to ensure adequate single ventricular filling and adequate cardiac output. There is evidence that patients with Fontan surgery increase pulmonary resistance over time. The increase in pulmonary resistance in these patients may result from several factors, and above all from the progressive dysfunction of a single systemic ventricle and the lack of a subpulmonary chamber ensuring pulsatile pulmonary flow. Although the Fontan operation in many patients with an univentricular heart is a very good method of palliative treatment, which undoubtedly extends the survival of children born with this heart defect, it also inevitably leads to severe complications developing over the years. Patients after the Fontan operation are also characterized by a significant reduction in exercise capacity, which is observed both in clinical practice in reference centres dealing with patients with congenital heart defects, and in multi-centre studies. Among other things, it was shown that children after the Fontan operation obtained 30% lower values of peak oxygen uptake in the ergospirometric test compared to the control group of healthy children (Amadero P et al., Heart 2018). The reduced exercise capacity of patients and the development of Fontan circulatory complications affect both the quality of life and the prognosis of adult patients with univentricular heart.
1 trial -
20186
Bayer AG
Treatment of children with chronic kidney disease and proteinuria
1 trial -
2021/3336
The George Institute
Maintenance treatment in metastatic non-squamous lung cancer
1 trial -
2023/3720 UMBRELLA
The George Institute
patients with a positive status for molecular residual disease (MRD) [MRD (+)] 2 to 5 months after the end of standard end of standard curative treatment
1 trial -
2024/4031
The George Institute
Patients with primary HPV high-grade squamous intra-epithelial lesions (HSIL) at any site (vulvar VIN, vaginal VaIN, penile (PeIN), cervical CIN, anal AIN) at the time of treatment.
1 trial -
61186372HNC3001
Janssen-Cilag International N.V.
Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
1 trial -
APHP240909
Pari Pharma GmbH
Patient with stabilized SSc-ILD (as defined by a decline of FVC ≤ 5%) following RTX induction treatment
1 trial -
AXS-05
Axsome Therapeutics
Treatment Resistant Major Depressive Disorder
1 trial -
Adjuvant chemotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Total Neoadjuvant Treatment
1 trial -
BGB-11417-304
BEONE MEDICINES AUS PTY LTD
treatment-naive Chronic Lymphocytic Leukemia
1 trial -
BX44273
Hoffmann-La Roche
This is an extension study designed to provide continued treatment for eligible patients with cancer who were previously enrolled and treated in a Genentech/Roche study (the parent study), and do not have access to the treatment locally
1 trial -
CBD 100 mg/mL Oral Solution
COGNITION THERAPEUTICS INC
Treatment Resistant Psychosis
1 trial -
CL3-95031-007
The George Institute
Locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 or 2 systemic treatment regimens
1 trial -
CLIN-10200-458
Ipsen
Treatment of moderate to severe glabellar lines
1 trial -
Combination Treatment of PDS0101 and Pembrolizumab
PDS Biotechnology Corp
Recurrent Head and Neck Cancer
1 trial -
Conventional medical treatment
Lxo Ireland Designated Activity Company
Coronary Atherosclerosis and Other Heart Disease
1 trial -
D5180C00016
AstraZeneca AB
Severe Uncontrolled Asthma Asthma (an illness that causes breathing difficulty) that is not fully controlled, so that asthma attacks are still occurring despite the use of other available treatments
1 trial -
DAPA-PedHKD
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Pediatric Hereditary Kidney Diseases
1 trial -
DIDaC/ NVALT35
Disc Medicine
Patients with advanced, metastatic NSCLC that have not progressed on a standard of care immunotherapy regimen 6 months after initiation of first line treatment.
1 trial -
Discontinuation antipsychotic treatment
Lxo Ireland Designated Activity Company
Psychosis Nos/Other
1 trial -
Docetaxel+lobaplatin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma
1 trial -
Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment
United Therapeutics Europe Ltd
COVID19
1 trial -
EP0165
Lacuna Pharma Pty Ltd
Treatment of stereotypical prolonged seizure
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.